This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Rheumatoid arthritis
  • /
  • NRAS position paper on biosimilar medicines Update...

NRAS position paper on biosimilar medicines Updated February, 2019

Read time: 1 mins
Last updated:21st Jan 2020

As more biosimilars enter the UK market, especially those administered by the sub-cutaneous route, the reality is that patients are being switched from a biologic on which they may be stable and responding well, to a biosimilar. This can be worrying for patients unless handled properly and with due opportunity for discussion, enabling the patient to ask any questions they may have about being switched to a biosimilar. In this position paper we set out our recommendations for a national best practice approach to be taken.


Read full guideline